Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model

Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model.

Full text not available from this repository.
Item Type: Article
Status: Published
Official URL: https://doi.org/10.1016/j.ejpb.2020.11.019
Journal or Publication Title: European Journal of Pharmaceutics and Biopharmaceutics
Volume: 158
Page Range: pp. 166-171
Date: 2021
Divisions: Tuberculosis
Depositing User: General Admin
Identification Number: 10.1016/j.ejpb.2020.11.019
ISSN: 09396411
Date Deposited: 10 Jun 2021 06:43
Abstract:

Combination treatment using bacteriophage and antibiotics is potentially an advanced approach to combatting antimicrobial-resistant bacterial infections. We have recently developed an inhalable powder by co-spray drying Pseudomonas phage PEV20 with ciprofloxacin. The purpose of this study was to assess the in vivo effect of the powder using a neutropenic mouse model of acute lung infection. The synergistic activity of PEV20 and ciprofloxacin was investigated by infecting mice with P. aeruginosa, then administering freshly spray-dried single PEV20 (106 PFU/mg), single ciprofloxacin (0.33 mg/mg) or combined PEV20-ciprofloxacin treatment using a dry powder insufflator. Lung tissues were then harvested for colony counting and flow cytometry analysis at 24 h post-treatment. PEV20 and ciprofloxacin combination powder significantly reduced the bacterial load of clinical P. aeruginosa strain in mouse lungs by 5.9 log10 (p < 0.005). No obvious reduction in the bacterial load was observed when the animals were treated only with PEV20 or ciprofloxacin. Assessment of immunological responses in the lungs showed reduced inflammation associating with the bactericidal effect of the PEV20-ciprofloxacin powder. In conclusion, this study has demonstrated the synergistic potential of using the combination PEV20-ciprofloxacin powder for P. aeruginosa respiratory infections.

Copyright © 2020 Elsevier B.V. All rights reserved.

Creators:
Creators
Email
Lin, Yu
UNSPECIFIED
Quan, Diana
UNSPECIFIED
Chang, Rachel Yoon Kyung
UNSPECIFIED
Chow, Michael Y.T.
UNSPECIFIED
Wang, Yuncheng
UNSPECIFIED
Li, Mengyu
UNSPECIFIED
Morales, Sandra
UNSPECIFIED
Britton, Warwick J.
UNSPECIFIED
Kutter, Elizabeth
UNSPECIFIED
Li, Jian
UNSPECIFIED
Chan, Hak-Kim
UNSPECIFIED
Last Modified: 10 Jun 2021 06:43
URI: https://eprints.centenary.org.au/id/eprint/1051

Actions (login required)

View Item View Item